Telix Pharmaceuticals Limited
TLX
$10.71
-$0.03-0.28%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 0.00% | 5.91% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.00% | 5.91% | |||
| Cost of Revenue | 0.00% | 10.36% | |||
| Gross Profit | 0.00% | 1.21% | |||
| SG&A Expenses | 0.00% | -0.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 0.00% | -708.57% | |||
| Total Operating Expenses | 0.00% | 6.93% | |||
| Operating Income | 0.00% | -28.56% | |||
| Income Before Tax | 0.00% | 91.11% | |||
| Income Tax Expenses | 0.00% | 273.07% | |||
| Earnings from Continuing Operations | 0.00% | -110.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 0.00% | -110.86% | |||
| EBIT | 0.00% | -28.56% | |||
| EBITDA | 0.00% | -22.34% | |||
| EPS Basic | 0.00% | -108.82% | |||
| Normalized Basic EPS | 0.00% | -380.77% | |||
| EPS Diluted | 0.00% | -144.12% | |||
| Normalized Diluted EPS | 0.00% | -380.77% | |||
| Average Basic Shares Outstanding | 0.00% | 0.40% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||